Novel aminobenzimidazoles as selective MCH-R1 antagonists for the treatment of metabolic diseases

Bioorg Med Chem Lett. 2006 Oct 15;16(20):5427-31. doi: 10.1016/j.bmcl.2006.07.058. Epub 2006 Aug 2.

Abstract

A series of novel aminobenzimidazoles was prepared and evaluated for h-MCH-R1 antagonist properties. Most of the compounds showed excellent h-MCH-R1 binding affinity as well as mouse ex vivo binding. Compounds 9 and 18 were active in mouse DIO studies at 30mpk.

MeSH terms

  • Animals
  • Anti-Obesity Agents / chemistry
  • Anti-Obesity Agents / pharmacology*
  • Benzimidazoles / chemistry
  • Benzimidazoles / pharmacology*
  • Benzimidazoles / therapeutic use*
  • Binding, Competitive / drug effects
  • Diet
  • Disease Models, Animal
  • Drug Evaluation, Preclinical
  • Eating / drug effects
  • Humans
  • Metabolic Diseases / drug therapy*
  • Mice
  • Mice, Obese
  • Molecular Conformation
  • Obesity / drug therapy
  • Rats
  • Receptors, Somatostatin / antagonists & inhibitors*
  • Stereoisomerism
  • Structure-Activity Relationship

Substances

  • Anti-Obesity Agents
  • Benzimidazoles
  • MCHR1 protein, human
  • Receptors, Somatostatin